Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH3: Ruxolitinib vs best available therapy in steroid-refractory chronic graft-versus-host disease
jRCT2080223697Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2017
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of ruxolitinib in steroid-refractory chronic graft-versus-host disease (SR-cGVHD) (2 arms), sponsored by Novartis. Started Oct 2017; status: completed.
02
Drugs
03
Conditions
steroid-refractory chronic graft-versus-host disease (SR-cGVHD)
Beyond the preview
Go deeper on jRCT2080223697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223697.